Your browser doesn't support javascript.
loading
Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression.
Kamal, Mohamed A; Gieschke, Ronald; Lemenuel-Diot, Annabelle; Beauchemin, Catherine A A; Smith, Patrick F; Rayner, Craig R.
Afiliación
  • Kamal MA; Department of Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, New York City, New York, USA.
  • Gieschke R; Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Lemenuel-Diot A; Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Beauchemin CA; Department of Physics, Ryerson University, Toronto, Ontario, Canada.
  • Smith PF; Monash Institute of Pharmaceutical Sciences, Melbourne, Australia d3 Medicine LLC, Parsippany, New Jersey, USA.
  • Rayner CR; Monash Institute of Pharmaceutical Sciences, Melbourne, Australia University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.
Antimicrob Agents Chemother ; 60(3): 1953, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26921415
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Antimicrob Agents Chemother Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Antimicrob Agents Chemother Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos